Introduction
Gentamicin is the preferred antimicrobial agent for the treatment of Gram-negative infections in neonates. 1, 2 Therapeutic drug monitoring is needed since it has a narrow therapeutic index. [3] [4] [5] Once daily dosing (ODD) of gentamicin (4 mg/kg IV q24 hours) has been used in the normal newborn nursery at Parkland Memorial Hospital (PMH) since 2000. [6] [7] [8] The pharmacodynamic characteristics of aminoglycosides that allow the use of once-daily dosing include concentration dependent (Cmax/MIC ratio) killing, 2,3,9 postantibiotic effect with leukocyte enhancement, 10, 11 and prevention of adaptive resistance. 10, 12, 13 Some institutions still utilize other extended interval dosing regimen for gentamicin among preterm infants. For 30-34 weeks gestation ≤7days old, gentamicin is given at 4.5 mg/kg every 36 hours (hrs) and for ≤29 weeks gestation ≤7days old 5 mg/kg every 48 hrs is recommended. 14, 15 Since December 2005, PMH had changed to ODD dosing regimen of gentamicin for preterm infants 27-34 weeks gestation at 3 mg/kg and for ≤26 weeks gestation at 2.5 mg/kg with good pharmacokinetic-pharmacodynamic profiles. 7 Gentamicin clearance (GentCL) correlates with glomerular filtration rate (GFR), 2, 3, 16 which in turn may be affected by prenatal exposure to maternal corticosteroids given for promotion of lung maturation. Antenatal exposure to dexamethasone may enhance renal tubular sodium reabsorption immediately after birth. 17 This may be mediated by earlier maturation of renal tubules through activation of tubular Na+-K+ ATPase enzymatic system. 17 Prenatal exposure to indomethacin or betamethasone can significantly affect the renal function of preterm infants after birth. Antenatal exposure to betamethasone with indomethacin may significantly increase GFR. 18 Previous reports in rat model suggest that glucocorticoid-induced (methylprednisolone) increase GFR is associated with increase in glomerular plasma flow rate. 19, 20 However, the effect of prenatal exposure to indomethacin on GFR or on GentCL when given simultaneously with steroid has not been fully elucidated.
The main objective of this study was to determine the gentamicin pharmacokinetic (PK)-pharmacodynamic (PD) profiles of ODD versus q18h dosing regimens and to characterize the effect of antenatal steroid exposure on GentCL . We hypothesized that ODD of gentamicin has better PK-PD profiles than q18h regimen, and that antenatal exposure to steroids affects GentCL (a surrogate marker of GFR).
Methods
This is a retrospective cohort study of preterm infants gestational age ≤34 weeks gestation and ≤7 days old who received gentamicin intravenously for >48 hrs for possible Gram-negative infection. This was done at the normal newborn nursery and nursery intensive care unit of PMH from January 2005 -June 2007. During those periods, PMH has an estimated 16,000 deliveries annually. Medical records were reviewed and abstracted for demographic and clinical data.
On December 2005, administration of gentamicin to preterm infants (gestational age 27-34 weeks) in the neonatal intensive care unit at PMH changed from 2.5 mg/kg q18h dosing regimen to ODD (3 mg/kg). Infants with GA ≤ 26 wk continued to receive ODD (2.5 mg/kg). Serum creatinine (Screa) was performed as part of the patient's medical care and creatinine clearance (CreaCL) was estimated using Schwartz method. 21 Gentamicin peak (1 hr) and trough (23 hrs) concentrations were obtained after the 3 rd dose considered the steady state per PMH nursery protocol. The serum peak and trough concentrations were determined by fluorescence polarization immunoassay. 3 The sensitivity limit of this assay (AxSYM, Abbott Laboratories, Abbott Park, IL, USA) is 0.3 mg/L with coefficient of variation <5%. 15 Pharmacokinetic profiles were determined using standard non-compartmental methods. 22 
A. PK-PD profiles of gentamicin ODD versus every 18 hours
Desired gentamicin peak (5-12 mcg/mL) and trough (<2 mcg/mL) concentrations 2, 3, 14, 15 were achieved in 80% (95%CI, 72-86) on ODD vs. 47% (95%CI, 36-58) on q18h (p<0.001). (Figure 2 )
The PK profile of ODD includes Ke 0.07 ± 0.02 h -1 , t1/2 10.3 ± 2.4 hrs, Cmax 7 ± 1.4 mcg/mL, Cmin 1.4 ± 0.5 mcg/mL, Vd 0.5 ± 0.2 L/kg, CL 38.6 ± 11.5 mL/kg·hr, and AUC 82 ± 8 mcg·mL/hr. The PK profile of q18h showed Ke 0.08 ± 0.03 h -1 , t1/2 9.1 ± 2.9 hrs, Cmax 6.7 ± 1.2 mcg/mL, Cmin 1.7 ± 0.6 mcg/mL, Vd 0.5 ± 0.2 L/kg, CL 42.2 ± 10.4 mL/kg·hr, and AUC 63 ± 13 mcg·mL/hr. Target drug exposure (AUC 72 mcg/mL hr) 3 was achieved in 73% (89/122) of infants on ODD vs. 22% (16/73) of those on the q18h regimen (p < 0.001). (Figure 2) A desired Cmax/MIC (1 mcg/mL) ratio of 8:1 2, 3, 9, 14 was achieved in 33% (95%CI, 25-42) of infants on ODD vs. 23% (95%CI, 15-34) on q18h regimen (p = 0.19). ( Figure   2 ) B. PK-PD profiles of gentamicin ODD: Gestational age ≤26 weeks versus 27-34 weeks Desired gentamicin peak (5-12 mcg/mL) and trough (<2 mcg/mL) concentrations 2, 3, 14, 15 (p =0.06), the target drug exposure (AUC 72 mcg/mL hr) 3 (p =0. 17) , and the desired Cmax/MIC (1 mcg/mL) ratio of 8:1 2,3,9,14 (p =0. 23) were not significantly different between gestational age ≤26 weeks versus 27-34 weeks using ODD gentamicin. ( Figure   3 )
C. Gentamicin clearance according to antenatal exposure to steroid with or without postnatal exposure to indomethacin 129 (66%) infants did not receive either steroid or indomethacin (Group A), 42 (22%) was exposed to steroid antenatally only (Group B), 14 (7%) received indomethacin postnatally (Group C), and 10 (5%) was exposed to steroid antenatally and received indomethacin postnatally (Group D). (Figure 4) There was a trend for decrease GentCL in preterm infants that received antenatal steroid alone (Group B, GentCL = 37.1 ± 8.2, p=0.06) and those who received antenatal steroid and postnatal indomethacin (Group D, GentCL = 36.4 ± 7.1, p=0.28) compared to those who did not receive either medications (Group A, GentCL = 41.3 ± 12.5).
GentCL was significantly lower among infants exposed to antenatal steroids than in those whose mothers did not receive steroids (37 ± 8 mL/kg·hr vs. 42 ± 13 mL/kg·hr, p = 0.04). The mean decrease in GentCL was approximately 4.6 ± 8 mL/kg·hr. There was no significant steroid and indomethacin interaction (p>0.86).
D. Clinical response and safety
All patients improved clinically in response to treatment with ampicillin and gentamicin for neonatal sepsis regimen. No patients had Gram negative bacteremia, meningitis, or brain abscess.
All patients tolerated gentamicin and there were no severe adverse events requiring drug discontinuation. Of those patients with available serum creatinine values as part of their medical care while on gentamicin, only one developed renal failure that eventually died. Majority of patients passed their newborn hearing evaluations except for three infants who failed the initial hearing test and on follow up one was diagnosed with retrocochlear pathology, another showed normal hearing evaluation, and in another the repeat hearing test was not performed because of death.
Microbiologic efficacy cannot be determined since no Gram negative organism was isolated during the study period thus, actual minimum inhibitory concentration cannot be used for PD calculations.
Discussion
The pharmacokinetic and pharmacodynamic profiles of gentamicin are improved by ODD in preterm infants. ODD gentamicin regimen achieved desired therapeutic concentrations and PK-PD profiles compared to every 18 hour dosing regimen in preterm neonates. Gentamicin clearance was significantly affected in infants exposed to antenatal steroids but not in those postnatally treated with indomethacin.
The desired PK-PD profiles were better using ODD of gentamicin in our patients compared to q18 hr regimen. More patients achieved the desired peak and trough using ODD regimen. Because of the narrow therapeutic index of gentamicin [3] [4] [5] we continue to follow the gentamicin peak and trough concentrations. These values are readily available in most clinical settings with results available usually after several hours. These therapeutic ranges may be followed by clinicians to guide their clinical management and individualize treatment. 3 There were more preterm infants who achieved the target drug exposure using ODD of gentamicin. It was previously suggested that gentamicin AUC approach should be followed in dose-individualization. 3 This was based on the principle that the same total dose given over 24 hrs should be given using individualization of therapy with the conventional or multiple dosing regimens. Assuming a one-compartment model, drug exposure can be calculated for each patient and subsequent doses may be adjusted to achieve target AUC which is associated with the efficacy of aminoglycosides. 2 We used a desired Cmax/MIC ratio of 8:1 since this was recommended as the useful range of bactericidal activity against most bacteria. This bactericidal effect is usually about 5-10 times the MIC of the organism. 2, 3, 9, 14 In our patients, there was a trend to achieve this PD index using the ODD regimen compared to q18h.
The desired gentamicin therapeutic ranges (peak and trough), target drug exposure and a desired Cmax/MIC ratio were very similar between preterm newborns ≤26 weeks and those infants 27-34 weeks gestation. This strongly suggests that desired PK-PD indices may be achieved using ODD regimen in preterm infants. There was a trend to achieve more target drug exposure among infant ≤26 weeks gestation than those born at 27-34 weeks. This may be associated with longer half-life of gentamicin which may approach >10 hours among very low birth weight infants with gestational age <31 weeks. 15 In preterm infants this may be due to larger extracellular fluid and volume of distribution resulting in reduced clearance. 2, 16 This may significantly affect the drug exposure (AUC = dose given/ Cl) among infants with very low birth weight.
There are extended interval dosing regimens other than ODD for gentamicin.
Lanao, J.M., et al. had described the PK basis for the use of extended interval dosing regimen of gentamicin for neonates using population PK modeling to achieve desired serum concentrations. 15 However, these findings should be correlated with clinical outcome and patient safety as well as microbiologic efficacy. One of the strengths of our research was to determine not only the clinical outcome but the patient safety as well with ODD regimen through a retrospective cohort design. We were not able to establish microbiologic efficacy since no infant had a positive blood or cerebrospinal fluid culture for Gram negative organisms. Thus, we were unable to calculate the PD profile using actual MIC values. However, we estimated the desired PD index of Cmax/MIC ratio of ≥ 8:1 2, 3, 9, 14 assuming an MIC value of 1 mcg/mL. GentCL was significantly affected by antenatal steroid exposure. In our patients, contrary to previous reports, 17, 18 exposure to dexamethasone or betamethasone significantly decreased GentCL. The effect was consistent in the groups of infants that were exposed to antenatal steroid without postnatal indomethacin (Group B) and in those who were exposed to antenatal steroid with postnatal indomethacin (Group D). (Figure 4) There was no evidence to support that the exposure to steroid and indomethacin in decreasing GentCL was synergistic or additive. Our finding does not support previous studies on enhanced GentCL associated with antenatal exposure to steroid. 17, 18 The importance of this study has implications in guiding clinicians in the therapeutic management of preterm infants. ODD gentamicin may be more practical and reported prenatal exposure to dexamethasone 17 or betamethasone 18 may exert significant effect on the enhanced maturation of renal function in preterm infants. Both synthetic glucocorticoid have equivalent potency. 18 Finally, we did not control or take into consideration other medications that the infants were receiving during the study period or clinical parameters that may affect the renal function such as sepsis, patent ductus arteriosus (PDA), and those on extracorporeal membrane oxygenation (ECMO). 2 These conditions (severe infections, PDA, ECMO) have been associated with increase in volume of distribution requiring higher dosing regimen of gentamicin to achieve desired peak concentrations. 3 In conclusion, gentamicin ODD regimen is clinically effective and safe among preterm infants (2.5 mg/kg for ≤26 weeks gestation and 3 mg/kg for 27-34 weeks). The PK-PD profiles (desired peak/ trough, target drug exposure, and desired Cmax/MIC ratio) were achieved among preterm infants with ODD. Antenatal steroid exposure can significantly affect GentCL of preterm infants that cannot be explained by indomethacin exposure postnatally. We recommend prospective evaluation of the PK-PD profile of ODD gentamicin regimen in preterm infants and correlating them with clinical outcome and microbiologic efficacy, as well as the effect of antenatal steroid exposure on GentCL. 
